# Safety and Pharmacokinetics of Intravenous and Oral Posaconazole in Immunocompromised Children (MK-5592-097)

> **NCT02452034** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 118 (actual)

## Conditions studied

- Neutropenia

## Interventions

- **DRUG:** Posaconazole IV solution
- **DRUG:** Posaconazole powder for oral suspension

## Key facts

- **NCT ID:** NCT02452034
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-07
- **Primary completion:** 2018-06-26
- **Final completion:** 2018-09-03
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2019-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02452034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02452034, "Safety and Pharmacokinetics of Intravenous and Oral Posaconazole in Immunocompromised Children (MK-5592-097)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02452034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*